Device choice has long been a driver for certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United States, device may become an even more important driver of physician choice within respiratory therapies. This report uses a conjoint analysis to examine the relative importance of specific device choice (MDI, DPI, SMI, and nebulizer), device features (e.g., inhalation counter, data capture), and availability of alternatives against the choice of molecule. Both currently available drug/device franchises and hypothetical combinations are considered. Additionally, respiratory nurses are interviewed to assess how patients are introduced to new devices and determine which features are most desirable in clinical practice.
DRG’s special topics reports provide quantitative insight into U.S. physician perceptions of key treatment drivers and goals and the current level of unmet need for inhaler technologies. Commercial opportunities are analyzed, and the extent to which emerging therapies and novel device features may capitalize on these opportunities is evaluated.